Fexinidazole for human African trypanosomiasis: the challenge of accessibility

This issue of The Lancet Global Health features two Articles on fexinidazole treatment for human African trypanosomiasis. One Article by Victor Kumeso and colleagues1 on gambiense human African trypanosomiasis, the other by Enock Matovu and colleagues2 on rhodesiense human African trypanosomiasis. The Article on gambiense human African trypanosomiasis is about widening eligibility criteria for fexinidazole treatment, including women in their second and third trimester of pregnancy or lactating, as well as outpatients.